



## REMARKS


Reconsideration and withdrawal of the rejection with respect to all of the claims now in the application, i.e., namely claims 34 to 43, is respectfully requested in view of the foregoing amendments and the following remarks.

The Office Action states that the reply filed on March 6, 2001 was not fully responsive to the prior Office Action because Applicant had not responded to the rejection under 35 U.S.C. §112, 1st paragraph as per §7, page 6 of the Office Action. In particular, the Examiner objected to the phrase "which when exposed to a preselected substance results in at least 3-45% mediator release". To resolve this objection, Applicant has deleted the objected-to language from the claim.

In view of the foregoing, it is now believed the above noted §112 rejection has been overcome and, for the reasons previously advanced, it is respectfully submitted that the claims are patentably distinguishable over the art of record. Accordingly, reconsideration and withdrawal of the rejection and allowance of the claims are earnestly solicited.

Respectfully submitted,

GALGANO & BURKE



---

Thomas M. Galgano  
Registration No. 27,638  
300 Rabro Drive - Suite 135  
Hauppauge, NY 11788  
Tel: (631) 582-6161  
Fax: (631) 582-6191

Enclosure: Marked up version of amended claim

F:\public\G&B#1\615\615-25\RESPTOQA.WPD

copy

37. (amended) A method according to claim 34 wherein said cell line is a [high-]secretor variant [which when exposed to a preselected substance results in at least 3-45% mediator release].